Varex Imaging (VREX), the oft-overlooked provider of X-ray components and imaging solutions, finds itself in a precarious spot as of early 2026, trading at levels that scream “value trap” to the undiscerning eye. While headline revenue growth and analyst price targets paint a rosy rebound picture, a deeper dive reveals eroding margins, persistent profitability volatility, and a parade of insider sells with zero buys—a contrarian red flag in a sector where healthcare demand should be a tailwind. Spun off from Varian Medical Systems in 2016 amid a wave of medical device divestitures, Varex has battled supply chain snarls from COVID-19 (triggering a brutal 2020 net loss of $57 million, down 462% from 2019’s $16 million profit) and semiconductor shortages that hammered imaging tech through 2022-2024. Yet, as stock lows plumbed 6.76 in 2025 amid these woes, today’s price hovers well below historical highs, decoupling from fundamentals in a way that demands skepticism rather than blind enthusiasm.
Revenue Growth: Steady but Stagnant on a Per-Employee Basis
Revenue has been the one consistent bright spot, climbing from $620 million in 2016 to a peak of $893 million in 2023—a compound annual growth rate of about 4.8%. But peel back the layers, and revenue per employee tells a grimmer tale: peaking at $442,929 in 2016 before sliding to $351,917 by 2025, a 20% drop despite headcount ballooning from 1,400 to 2,400 workers. This efficiency erosion—critical because it flags bloated operations in a capital-intensive industry—correlates tightly with gross margin compression from 40.1% in 2016 to 31.7% in 2024, before a projected uptick to 34.4% in 2025. Analysts forecast revenue rebounding to $956 million by 2028 (up 18% from 2024’s $811 million dip, or 5% CAGR), driven by medical and industrial imaging demand post-supply glut. However, this assumes no repeat of 2020’s 5.4% revenue plunge amid pandemic shutdowns or ongoing China trade tensions, which have squeezed component exports.
Stock price action mirrors this uneven trajectory: highs crested above 40 in 2017-2018 on revenue surges, but cratered to 10-15 range by 2024-2025 as growth faltered. At current levels, the price-to-sales ratio has compressed to sub-1.0x territory (from 1.8x in 2017), making it look cheap—but cheap for a reason, as sales growth decoupled from profitability.
Profitability: A Volatile Mess Masking Structural Weakness
Earnings before tax (EBT) reads like a horror novel: $105 million in 2016, plummeting 29% to $75 million in 2017, then nosediving to a $73 million loss in 2020 and another projected $59 million hole in 2025. EBT margins? A feast-or-famine 16.9% peak to negative 9.8% troughs. Net income swung wildly too—from $69 million (2016) to $48 million loss in 2024 (down 200% from 2023’s $48 million profit)—with ROE cratering to -13.7% in 2025 from 8.4% in 2023. These metrics matter because in imaging, where R&D and capex chew 5-6% of sales annually (capex/share steady at -0.5 to -0.8), thin margins amplify operational hiccups into existential threats.
Free cash flow per share offers faint hope, rebounding to $2.18 in 2023 from negative territory, but projections halt abruptly, implying uncertainty. Correlate this to depreciation spiking 226% from $15 million (2016) to $124 million (2025)—likely from accelerated asset writes in a post-COVID capex hangover—and you see why returns on invested capital (ROIC) languish below 6% most years, versus industry peers north of 10%. Stock prices tanked in sync: 2020 lows at 10.37 amid the loss, recovering modestly to 2025 highs of 15.46 before fading, underscoring how earnings volatility has crushed multiple expansion (PE ratios from 15x to undefined losses).
Balance Sheet: Levered but Liquid, with Working Capital Cushion
Shareholders’ equity grew steadily to $581 million in 2023 (up 10.4% CAGR from 2016’s $526 million) before a 16% trim to $487 million by 2025, supporting a book value per share dip from 14.06 to 11.75. Total debt hovered around $400-450 million (peaking at $455 million in 2020, up 15% from 2019), but net debt eased to $212 million by 2025 (down 13% from 2024), yielding a manageable EV/sales of 0.86x. Working capital ballooned to $455 million, a 61% rise from 2016, providing ammo for the $20-40 million annual capex.
Yet, PB ratios contracting to 1.1x signals market doubt on asset quality—especially post-2016 spin-off when Varex inherited Varian’s legacy debt without the pharma upside. Stock development here diverges: while book value climbed, prices halved from 2018 highs, implying the market prices in dilution risk from 41 million shares (up 10% since 2016) or hidden liabilities.
Insider Transactions: All Sells, No Confidence Signal
Zero buys across 12 months through February 2026, but sells totaling over $240,000 in value—led by the President/CEO dumping 8,749 shares in April 2025 (at implied ~$11/share), SVP/CLO 4,007 shares in March, and a Director offloading 5,575 shares across June/August. CHRO and others piled on, with no offsetting purchases. In a small-cap like VREX, this unanimity screams caution: insiders aren’t buying the rebound narrative, offloading amid projected 2026 EPS recovery to $0.61 (from 2025’s -$1.70 loss, a 136% swing). Historically, such one-sided activity precedes downside—recall pre-2020 sells before the COVID cliff.
Valuation: Cheap Multiples, but Earnings Quality Lacking
PS ratios slid from 1.6x (2016) to 0.6x, EV/FCF ballooned during loss years, yet forward PE at 22x for 2026 looks reasonable on $26 million net income (up 137% from 2025 loss). Cash flow per share averaged $1.50 historically, supporting dividends or buybacks—none evident lately. Against peers in medtech imaging, VREX trades at a discount, but EV/sales trending to 0.59x by 2028 assumes flawless execution.
Stock evolution underscores the disconnect: from 2017-2019 highs (35-43) on growth hype, to 2024 lows (10) on margin squeezes, now stabilizing below prior troughs despite revenue projections.
Future Outlook: Analyst Optimism vs. Contrarian Risks
Projections pencil pretty: revenue to $956 million (2028), EPS stabilizing at $0.61-0.71, ROA rebounding to 5.2%. This bets on industrial X-ray demand (post-2023 semiconductor normalization) and medical CT boom, echoing post-2016 spin-off gains. But risks loom—gross margins must hold 34%+ amid China decoupling (Varex’s key market) and FDA scrutiny on imaging radiation safety.
Analyst targets imply 18% upside to lows, 33% to average, 63% to highs from here—enticing, but contrarians note these often front-run reality in cyclicals. With insiders exiting stage left, 2024-2025 losses fresh, and efficiency metrics decaying, I’d wager on stagnation over moonshot. Varex isn’t doomed—healthcare seculars persist—but betting the farm ignores the pattern: growth without margins equals value traps. Watch for buybacks or margin inflection before piling in; otherwise, this is skepticism incarnate.
(Word count: 1,128)